Based on our data, the combination of TGFβ, IL-4, IL-10 and IL-13 was sufficient to obtain a fibroblast-like phenotype by circulating CD14+ monocytes, indicating that IL-4/IL-13 targeted therapy might be an attractive option against fibrogenesis in SSc (68). This evidence concerns the gene CD14 and systemic sclerosis.